Claims

1. Use of an anti-Interleukin-5 receptor (IL-5R) antibody in the manufacture of a medicament for reducing the numbers of peripheral blood basophils in an asthmatic subject,

wherein said antibody is to be parenterally administered to said subject between 0.01 to 0.25 mg/kg,

wherein said antibody comprises the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO:3; and an immunoglobulin Fc region comprising no fucose, and

wherein said antibody is to be administered to reduce the number of peripheral blood basophils from the asthmatic subject's circulation by 5 to 70 basophils/mm^3 by 24 hours post-administration.

2. The use of claim 1, wherein the reduction of basophils is reversible.

3. The use of claim 1 or 2, wherein the numbers of basophils are reduced to a level that is less than 9 basophils/mm^3.

4. The use of any one of claims 1 to 3, wherein there is a post-administration reduction in absolute basophil count of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at least 70 basophils/mm^3.

5. The use of any one of claims 1 to 4, wherein said subject's pre-administration absolute basophil count is between 5 and 500 basophils/mm^3.

6. The use of any one of claims 1 to 5, wherein said subject's pre-administration absolute basophil count is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 50, at least 60, at least 70, at least 100, at least 200, at least 300, at least 400, or at least 500 basophils/mm^3.